Current Opinion in Virology

Papers
(The TQCC of Current Opinion in Virology is 18. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2020-11-01 to 2024-11-01.)
ArticleCitations
Structure of SARS-CoV-2 spike protein150
Developing a direct acting, orally available antiviral agent in a pandemic: the evolution of molnupiravir as a potential treatment for COVID-19128
Considerations for the discovery and development of 3-chymotrypsin-like cysteine protease inhibitors targeting SARS-CoV-2 infection106
Current challenges to virus discovery by meta-transcriptomics68
Future considerations for the mRNA-lipid nanoparticle vaccine platform66
Zoonotic disease and virome diversity in bats63
Global overview and major challenges of host prediction methods for uncultivated phages62
Coronavirus entry: how we arrived at SARS-CoV-257
Structure and function of SARS-CoV-2 polymerase57
The virome of vector mosquitoes57
RNA viruses and the cGAS-STING pathway: reframing our understanding of innate immune sensing55
A structural view of the SARS-CoV-2 virus and its assembly55
Animal models for SARS-CoV-254
The healthy human virome: from virus–host symbiosis to disease51
Engineering therapeutic phages for enhanced antibacterial efficacy50
Recent advances in understanding plant antiviral RNAi and viral suppressors of RNAi46
Structure, function and assembly of the long, flexible tail of siphophages46
Viral Z-RNA triggers ZBP1-dependent cell death44
Cell-to-cell movement of plant viruses via plasmodesmata: a current perspective on potyviruses44
COVID-19, the first pandemic in the post-genomic era40
Anti-viral protective capacity of tissue resident memory T cells40
European regulatory aspects of phage therapy: magistral phage preparations40
Perspective on taxonomic classification of uncultivated viruses38
Host cell-intrinsic innate immune recognition of SARS-CoV-237
Interfering with SARS-CoV-2: are interferons friends or foes in COVID-19?37
Entry of influenza A virus into host cells — recent progress and remaining challenges36
Tombusviruses orchestrate the host endomembrane system to create elaborate membranous replication organelles35
Mitigation of evolved bacterial resistance to phage therapy34
Viral structural proteins as targets for antivirals32
Phage banks as potential tools to rapidly and cost-effectively manage antimicrobial resistance in the developing world32
Detection of viruses by inflammasomes31
Current view and perspectives in viroid replication30
Monoclonal antibodies against rabies: current uses in prophylaxis and in therapy30
Rotavirus cell entry: not so simple after all30
Adenovirus – a blueprint for gene delivery29
Hepatitis B virus–host interactions and novel targets for viral cure29
Drug resistance mutations in HIV: new bioinformatics approaches and challenges29
Animal models of SARS-CoV-2 transmission28
Epigenetic control of the Epstein-Barr lifecycle28
Digital phagograms: predicting phage infectivity through a multilayer machine learning approach28
Measles immunity and immunosuppression28
Immune system control of hepatitis C virus infection27
An overview of the current state of phage therapy for the treatment of biofilm-related infections26
Natural killer cells and unconventional T cells in COVID-1926
Molecular dynamics of the viral life cycle: progress and prospects25
Progress and pitfalls of a year of drug repurposing screens against COVID-1925
The gut virome in inflammatory bowel diseases24
Development of plant-made monoclonal antibodies against viral infections23
Proteases and variants: context matters for SARS-CoV-2 entry assays23
R gene mediated defense against viruses23
Targeting of viral RNAs by Upf1-mediated RNA decay pathways23
The long and winding road: human papillomavirus entry and subcellular trafficking23
Revisiting an old friend: new findings in alphavirus structure and assembly22
Mapping the diverse structural landscape of the flavivirus antibody repertoire22
UPR signaling at the nexus of plant viral, bacterial, and fungal defenses22
Remdesivir for the treatment of Covid-19: the value of biochemical studies22
Evolution of the interferon response: lessons from ISGs of diverse mammals21
Principles of epithelial homeostasis control during persistent human papillomavirus infection and its deregulation at the cervical transformation zone21
Tissues: the unexplored frontier of antibody mediated immunity21
Antiviral immunity triggered by infection-induced host transposable elements21
Broadly neutralizing antibodies against HIV-1 and concepts for application21
The enigmatic roles of Anelloviridae and Redondoviridae in humans20
Phage therapy for secondary bacterial infections with COVID-1920
Unresolved questions in the zoonotic transmission of MERS20
Assembly of the virome in newborn human infants20
Human genetic and immunological dissection of papillomavirus-driven diseases: new insights into their pathogenesis20
Shopping for phages? Unpacking design rules for therapeutic phage cocktails19
Virus genomics: what is being overlooked?19
The surface glycoproteins of hantaviruses18
Advances in human monoclonal antibody therapy for HBV infection18
The origin of Human Papillomavirus (HPV) — induced cervical squamous cancer18
The influence of microbiota-derived metabolites on viral infections18
Endocytosis of Bacteriophages18
Cryo-electron microscopy of nodavirus RNA replication organelles illuminates positive-strand RNA virus genome replication18
0.10668992996216